Todd L. Astor,1 Hilary J. Goldberg,2 Laurie D. Snyder,3 Andrew Courtwright,4 Ramsey Hachem,5 Tahuanty Pena,6 Lorenzo Zaffiri,3 Gerard J. Criner,7 Marie M. Budev,8 Tany Thaniyavarn,2 Thomas B. Leonard,9 Shaun Bender,9 Howard M Lazarus,10 Aliaa Barakat,11 Janis Breeze,12 Peter LaCamera13

1Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA; 2Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, MA, USA; 3Division of Pulmonary, Allergy and Critical Care Medicine, Duke University, Durham, NC, USA; 4Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA, USA; 5Division of Pulmonary and Critical Care, Washington University, St. Louis, MO, USA; 6Division of Pulmonary, Critical Care and Occupational Medicine, University of Iowa, Iowa City, IA, USA; 7Department of Thoracic Medicine and Surgery, Temple University, Philadelphia, PA, USA; 8Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA; 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 10Altavant Sciences, Inc, USA; 11ILD Collaborative, Boston, MA, USA; 12Clinical and Translational Science Institute, Tufts University, Boston, MA, USA; 13Division of Pulmonary, Critical Care and Sleep Medicine, St. Elizabeth’s Medical Center, Boston, MA, USA.

Introduction

  • Nintedanib and pirfenidone are anti-fibrotic medications that slow the progression of idiopathic pulmonary fibrosis (IPF).
  • Concern has been raised that anti-fibrotic medications may increase the risk of post-transplant complications such as delayed incisional healing or sternal or anastomotic dehiscence.
  • More data are needed on whether continuing antifibrotic therapy until the time of lung transplant increases the risk of complications.
Header - Navigation Icon